Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives $20.89 Consensus Target Price from Brokerages

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has been assigned a consensus recommendation of “Buy” from the ten brokerages that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, seven have given a buy rating and two have given a strong buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $20.89.

A number of equities research analysts recently issued reports on YMAB shares. Brookline Capital Management assumed coverage on shares of Y-mAbs Therapeutics in a report on Thursday, December 5th. They issued a “buy” rating and a $17.00 target price for the company. HC Wainwright reissued a “buy” rating and issued a $22.00 price objective on shares of Y-mAbs Therapeutics in a research report on Monday. Wedbush reaffirmed an “outperform” rating and set a $23.00 price target on shares of Y-mAbs Therapeutics in a research report on Friday, January 10th. Finally, Oppenheimer started coverage on Y-mAbs Therapeutics in a report on Monday, November 18th. They set an “outperform” rating and a $23.00 target price on the stock.

Institutional Investors Weigh In On Y-mAbs Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. State Street Corp raised its position in shares of Y-mAbs Therapeutics by 50.4% during the 3rd quarter. State Street Corp now owns 1,209,781 shares of the company’s stock valued at $15,909,000 after acquiring an additional 405,169 shares in the last quarter. Caligan Partners LP raised its stake in Y-mAbs Therapeutics by 105.3% during the third quarter. Caligan Partners LP now owns 1,195,253 shares of the company’s stock worth $15,718,000 after acquiring an additional 613,175 shares during the period. Geode Capital Management LLC boosted its stake in Y-mAbs Therapeutics by 6.2% in the third quarter. Geode Capital Management LLC now owns 813,489 shares of the company’s stock valued at $10,699,000 after acquiring an additional 47,846 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Y-mAbs Therapeutics by 15.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 484,431 shares of the company’s stock worth $5,853,000 after purchasing an additional 65,732 shares during the period. Finally, Millennium Management LLC lifted its holdings in shares of Y-mAbs Therapeutics by 23.8% in the 2nd quarter. Millennium Management LLC now owns 349,784 shares of the company’s stock worth $4,225,000 after purchasing an additional 67,233 shares during the last quarter. Institutional investors own 70.85% of the company’s stock.

Y-mAbs Therapeutics Stock Performance

Shares of YMAB stock opened at $6.33 on Friday. Y-mAbs Therapeutics has a 1 year low of $6.01 and a 1 year high of $20.90. The stock has a market cap of $283.51 million, a PE ratio of -11.72 and a beta of 0.69. The stock has a fifty day moving average price of $10.15 and a 200 day moving average price of $12.09.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its quarterly earnings data on Friday, November 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.02). Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. The firm had revenue of $18.46 million for the quarter, compared to analysts’ expectations of $23.38 million. During the same period in the previous year, the company posted ($0.18) EPS. As a group, equities research analysts predict that Y-mAbs Therapeutics will post -0.66 earnings per share for the current year.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.